MRAS

Summary

Gene Symbol: MRAS
Description: muscle RAS oncogene homolog
Alias: M-RAs, R-RAS3, RRAS3, ras-related protein M-Ras, muscle and microspikes RAS, ras-related protein R-Ras3
Species: human
Products:     MRAS

Top Publications

  1. Erdmann J, Grosshennig A, Braund P, König I, Hengstenberg C, Hall A, et al. New susceptibility locus for coronary artery disease on chromosome 3q22.3. Nat Genet. 2009;41:280-2 pubmed publisher
    ..We identified one new CAD risk locus on 3q22.3 in MRAS (P = 7.44 x 10(-13); OR = 1.15, 95% CI = 1.11-1.19), and suggestive association with a locus on 12q24...
  2. Kańtoch A, Gryglewska B, Wójkowska Mach J, Heczko P, Grodzicki T. Treatment of Cardiovascular Diseases Among Elderly Residents of Long-term Care Facilities. J Am Med Dir Assoc. 2018;19:428-432 pubmed publisher
    ..7%), BBs (45.3%), loop diuretics (LDs, 36%), mineralocorticoid-receptor antagonists (MRAs, 21.3%). HT was diagnosed among 98 study participants (51.9%) and in the majority of cases (76...
  3. Hosseini E, Moniri R, Goli Y, Kashani H. Purification of Antibacterial CHAPK Protein Using a Self-Cleaving Fusion Tag and Its Activity Against Methicillin-Resistant Staphylococcus aureus. Probiotics Antimicrob Proteins. 2016;8:202-210 pubmed
    ..Finally, inhibition zone in MRAS culture medium confirmed antibacterial activity of the protein...
  4. Endo T. Molecular mechanisms of skeletal muscle development, regeneration, and osteogenic conversion. Bone. 2015;80:2-13 pubmed publisher
    ..The small GTPase M-Ras is likely to participate in the ectopic calcification and ossification, as well as in osteogenesis during development. This article is part of a Special Issue entitled "Muscle Bone Interactions". ..
  5. Packham D, Kosiborod M. Potential New Agents for the Management of Hyperkalemia. Am J Cardiovasc Drugs. 2016;16:19-31 pubmed publisher
    ..and broad use of renin-angiotensin-aldosterone system (RAAS) inhibitors and mineralocorticoid receptor antagonists (MRAs), which improve patient outcomes but increase the risk of hyperkalemia, have led to a significant rise in ..
  6. Eschalier R, Chenaf C, Mulliez A, Yalioua A, Clerfond G, Authier N, et al. Impact of clinical characteristics and management on the prognosis of unselected heart failure patients. Cardiovasc Drugs Ther. 2015;29:89-98 pubmed publisher
    ..real-life HF data provide insight into prognostic factors and "real-world" pharmacological management in this unselected HF population, confirming the benefit of ACEi/ARB + BB ± MRAs on patient survival.
  7. Defilippis E, Desai A. Treatment of Hyperkalemia in Heart Failure. Curr Heart Fail Rep. 2017;14:266-274 pubmed publisher
    ..risk of hyperkalemia may be further moderated through the use of combined angiotensin-neprilysin inhibitors, novel MRAs, and novel potassium binding agents...
  8. Riester A, Reincke M. Progress in primary aldosteronism: mineralocorticoid receptor antagonists and management of primary aldosteronism in pregnancy. Eur J Endocrinol. 2015;172:R23-30 pubmed publisher
    ..Mineralocorticoid receptor antagonists (MRAs) are the most effective drugs to treat hypertension and hypokalemia in patients with PA...
  9. Zoheir K, Abd Rabou A, Harisa G, Kumar A, Ahmad S, Ansari M, et al. IQGAP1 gene silencing induces apoptosis and decreases the invasive capacity of human hepatocellular carcinoma cells. Tumour Biol. 2016;37:13927-13939 pubmed
    ..Furthermore, we observed that the mRNA levels of HRAS, KRAS, NRAS, and MRAS decreased upon IQGAP1 silencing...

More Information

Publications135 found, 100 shown here

  1. Kałużna Oleksy M, Kolasa J, Migaj J, Pawlak A, Lelonek M, Nessler J, et al. Initial clinical experience with the first drug (sacubitril/valsartan) in a new class - angiotensin receptor neprilysin inhibitors in patients with heart failure with reduced left ventricular ejection fraction in Poland. Kardiol Pol. 2018;76:381-387 pubmed publisher
    ..It was demonstrated that the use of sacubitril/valsartan in outpatients with HFrEF is safe and is associated with a significant clinical improvement. ..
  2. Youngstein T, Tombetti E, Mukherjee J, Barwick T, Al Nahhas A, Humphreys E, et al. FDG Uptake by Prosthetic Arterial Grafts in Large Vessel Vasculitis Is Not Specific for Active Disease. JACC Cardiovasc Imaging. 2017;10:1042-1052 pubmed publisher
    ..Despite the high frequency of graft-associated [18F]FDG uptake, sequential MRAs did not reveal arterial progression in 25 of 26 patients; the 1 remaining case showed minor progression limited to ..
  3. Shahid S, Shabana -, Cooper J, Beaney K, Li K, Rehman A, et al. Genetic risk analysis of coronary artery disease in Pakistani subjects using a genetic risk score of 21 variants. Atherosclerosis. 2017;258:1-7 pubmed publisher
    ..MIA3 rs17465637, CDKN2Ars10757274, DAB2IP rs7025486, CXCL12 rs1746048, ACE rs4341, APOA5 rs662799, CETP rs708272, MRAS rs9818870, LPL rs328, LPL rs1801177, PCSK9 rs11591147 and APOE rs7412 by TaqMan and KASPar allele discrimination ..
  4. Pellicori P, Cleland J. Heart failure with preserved ejection fraction. Clin Med (Lond). 2014;14 Suppl 6:s22-8 pubmed publisher
    ..treatments directed at congestion and hypertension, such as diuretics, mineralocorticoid receptor antagonists (MRAs) and angiotensin converting-enzyme inhibitors, may improve symptoms and probably do improve outcomes...
  5. Bhagirath D, Zhao X, Mirza S, West W, Band H, Band V. Mutant PIK3CA Induces EMT in a Cell Type Specific Manner. PLoS ONE. 2016;11:e0167064 pubmed publisher
    ..These results suggest that EMT is a cell type dependent phenomenon and does not dictate oncogenesis. ..
  6. Neefs J, van den Berg N, Limpens J, Berger W, Boekholdt S, Sanders P, et al. Aldosterone Pathway Blockade to Prevent Atrial Fibrillation: A Systematic Review and Meta-Analysis. Int J Cardiol. 2017;231:155-161 pubmed publisher
    ..0%) received an MRA (spironolactone or eplerenone). During follow-up, 204 (8.5%) patients treated with MRAs, developed AF, compared to 547 (18.6%) patients, without MRA treatment...
  7. Martens P, Nijst P, Dupont M, Mullens W. The Optimal Plasma Volume Status in Heart Failure in Relation to Clinical Outcome. J Card Fail. 2019;25:240-248 pubmed publisher
    ..Higher dosages of renin-angiotensin-aldosterone blockers are associated with higher odds of having an optimal PV status. ..
  8. Kobayashi M. Diffuse cerebrovascular dilation: Case report of amezinium metilsulfate-induced reversible cerebral vasoconstriction syndrome. Cephalalgia. 2016;36:289-93 pubmed publisher
    ..Nevertheless, follow-up MRAs disclosed widespread segmental vasoconstriction that resolved in two months...
  9. Filipe M, Meijers W, Rogier van der Velde A, de Boer R. Galectin-3 and heart failure: prognosis, prediction & clinical utility. Clin Chim Acta. 2015;443:48-56 pubmed publisher
    ..ACE) inhibitors, β-blockers, angiotensin receptor blockers (ARBs), mineralocorticoid receptor antagonists (MRAs), and implantable cardiac defibrillators, prognosis of HF patients remains poor...
  10. Masoumi A, Ortiz F, Radhakrishnan J, Schrier R, Colombo P. Mineralocorticoid receptor antagonists as diuretics: Can congestive heart failure learn from liver failure?. Heart Fail Rev. 2015;20:283-90 pubmed publisher
    ..Administration of natriuretic doses of mineralocorticoid receptor antagonists (MRAs) has been well established in management of cirrhotic patients...
  11. Madai V, von Samson Himmelstjerna F, Sandow N, Weiler F, Bauer M, Vajkoczy P, et al. Ultrahigh-field MPRAGE Magnetic Resonance Angiography at 7.0 T in patients with cerebrovascular disease. Eur J Radiol. 2015;84:2613-7 pubmed publisher
    ..TOF-MRA was performed at 3.0 T and MPRAGE-MRA at 7.0 T. Two radiologists rated the MRAs independently for overall quality and local arterial segment visualization...
  12. Sun Y, Jia X, Hou L, Liu X. Screening of Differently Expressed miRNA and mRNA in Prostate Cancer by Integrated Analysis of Transcription Data. Urology. 2016;94:313.e1-6 pubmed publisher
    ..In this regulatory network, 10 genes (BCL2, BNC2, CCND2, EPM2A, MRAS, NAV2, RASL12, STK33, TCEAL1, WWC2) were co-regulated by 5 miRNAs (hsa-miR-106b, hsa-miR-130b, hsa-miR-93, hsa-miR-..
  13. Fudim M, Liu P, Shrader P, Blanco R, Allen L, Fonarow G, et al. Mineralocorticoid Receptor Antagonism in Patients With Atrial Fibrillation: Findings From the ORBIT-AF (Outcomes Registry for Better Informed Treatment of Atrial Fibrillation) Registry. J Am Heart Assoc. 2018;7: pubmed publisher
    ..The mean patient age was 72.5 years, 56.3% were men, and 70.4% had paroxysmal AF. Among all patients taking MRAs, 434 (59.0%) had heart failure, 655 (89.0%) had hypertension, and 380 (51.6%) had both...
  14. Klenke F, Hoffmann D, Cross B, Siebenrock K. Validation of a standardized mapping system of the hip joint for radial MRA sequencing. Skeletal Radiol. 2015;44:339-43 pubmed publisher
    ..Sixty-nine consecutive intraarticular gadolinium-enhanced hip MRAs were evaluated. Radial sequencing consisted of 14 cuts orientated along the axis of the femoral neck...
  15. Keshavarz M, Mojra A. Dynamic modeling of breast tissue with application of model reference adaptive system identification technique based on clinical robot-assisted palpation. J Mech Behav Biomed Mater. 2015;51:269-78 pubmed publisher
    ..In this study a model reference adaptive system identification (MRAS) algorithm is utilized to estimate the dynamic behavior of breast tissue from mechanical stress-strain datasets...
  16. Ye S, Zhang L, Feng H. Marine ecological risk assessment methods for radiation accidents. J Environ Radioact. 2017;180:65-76 pubmed publisher
    ..the ERA approach and methodology for MRA are scientifically sound and effective in both the early and late stage of MRAs along with classic ERA Approach and the ERICA Integrated Approach...
  17. Piccaluga P, Navari M, De Falco G, Ambrosio M, Lazzi S, Fuligni F, et al. Virus-encoded microRNA contributes to the molecular profile of EBV-positive Burkitt lymphomas. Oncotarget. 2016;7:224-40 pubmed publisher
    ..Among others, we identified LIN28B, CGNL1, GCET2, MRAS, PLCD4, SEL1L, SXX1, and the tyrosine kinases encoding STK10/STK33, all provided with potential pathogenetic ..
  18. Cornelissen B, Schneiders J, Sprengers M, van den Berg R, van Ooij P, Nederveen A, et al. Aneurysmal Parent Artery-Specific Inflow Conditions for Complete and Incomplete Circle of Willis Configurations. AJNR Am J Neuroradiol. 2018;39:910-915 pubmed publisher
    ..Circle of Willis configurations were inspected for variations using multiple overlapping thin-slab-acquisition MRAs. Flow rates, velocity magnitudes, and pulsatility indices were calculated for each parent artery location in ..
  19. Korol S, White M, O Meara E, Tournoux F, Racine N, Ducharme A, et al. A comparison of the effects of selective and non-selective mineralocorticoid antagonism on glucose homeostasis of heart failure patients with glucose intolerance or type II diabetes: A randomized controlled double-blind trial. Am Heart J. 2018;204:190-195 pubmed publisher
    Mineralocorticoid receptor antagonists (MRAs) decrease morbidity and mortality in patients with heart failure (HF). However, spironolactone, a non-selective MRA, has been shown to exert a harmful effect on glucose homeostasis...
  20. Frank J, Lee S, McCormick F, Jordan M, Austell B, Slikker W, et al. Quantification and correlation of hip capsular volume to demographic and radiographic predictors. Knee Surg Sports Traumatol Arthrosc. 2016;24:2009-15 pubmed publisher
    ..The current study describes a reproducible radiographic measurement for hip capsule volumes from MRAs. Only gender was predictive of total capsular volume, femoral head volume, and true capsular volume...
  21. Sanders M, van Doormaal P, Beeftink M, Bots M, Fadl Elmula F, Habets J, et al. Renal artery and parenchymal changes after renal denervation: assessment by magnetic resonance angiography. Eur Radiol. 2017;27:3934-3941 pubmed publisher
    ..Primary outcome was the change in renal artery morphology and parenchyma. MRAs from 96 patients were analysed...
  22. Shahid S, Shabana N, Rehman A, Humphries S. GWAS implicated risk variants in different genes contribute additively to increase the risk of coronary artery disease (CAD) in the Pakistani subjects. Lipids Health Dis. 2018;17:89 pubmed publisher
    ..rs10757274 in CDKN2A gene, rs17465637 in MIA3 gene, rs7025486 in DAB2IP gene, rs17228212 in SMAD3 gene, rs981887 in MRAS gene and rs1746048 in CXCL12 gene, by TaqMan and KASPar allele discrimination techniques...
  23. O Donnell C, Kavousi M, Smith A, Kardia S, Feitosa M, Hwang S, et al. Genome-wide association study for coronary artery calcification with follow-up in myocardial infarction. Circulation. 2011;124:2855-64 pubmed publisher
    ..is evidence for concordance of SNP associations with both CAC and MI at a number of other loci, including 3q22 (MRAS gene), 13q34 (COL4A1/COL4A2 genes), and 1p13 (SORT1 gene)...
  24. Abulí A, Fernández Rozadilla C, Giráldez M, Muñoz J, Gonzalo V, Bessa X, et al. A two-phase case-control study for colorectal cancer genetic susceptibility: candidate genes from chromosomal regions 9q22 and 3q22. Br J Cancer. 2011;105:870-5 pubmed publisher
    ..susceptibility within the aforementioned linkage regions including PTCH1, XPA and TGFBR1 in 9q22-31, and EPHB1 and MRAS in 3q21-q24...
  25. Yin Y, Fang Z, Liu Y, Han F. Temperature-Insensitive Structure Design of Micromachined Resonant Accelerometers. Sensors (Basel). 2019;19: pubmed publisher
    Micromachined resonant accelerometers (MRAs), especially those devices fabricated by silicon on glass technology, suffer from temperature drift error caused by inherent thermal stress...
  26. Marciano D, Soize S, Metaxas G, Portefaix C, Pierot L. Follow-up of intracranial aneurysms treated with stent-assisted coiling: Comparison of contrast-enhanced MRA, time-of-flight MRA, and digital subtraction angiography. J Neuroradiol. 2017;44:44-51 pubmed publisher
    ..Both MRAs were unable to provide a precise evaluation of in-stent status but could detect parent vessel occlusion.
  27. Wirtwein M, Melander O, Sjögren M, Hoffmann M, Narkiewicz K, Gruchala M, et al. The Relationship Between Gene Polymorphisms and Dipping Profile in Patients With Coronary Heart Disease. Am J Hypertens. 2016;29:1094-102 pubmed publisher
    ..0% vs. 36.4%, P < 0.01). SNPs of the genes, MIA3, MRAS, PCSK9, SMG6, and ZC3HC1, were related to a higher risk of nondipping SBP and DBP status...
  28. Bustamante M, Gupta V, Carlhäll C, Ebbers T. Improving visualization of 4D flow cardiovascular magnetic resonance with four-dimensional angiographic data: generation of a 4D phase-contrast magnetic resonance CardioAngiography (4D PC-MRCA). J Cardiovasc Magn Reson. 2017;19:47 pubmed publisher
    ..The method was evaluated in ten healthy volunteers. Visual comparison of the 4D PC-MRCAs versus PC-MRAs generated from 4D Flow CMR using the traditional approach was performed by two observers using Maximum Intensity ..
  29. D Elia E, Krum H. Mineralcorticoid antagonists in heart failure. Heart Fail Clin. 2014;10:559-64 pubmed publisher
    Mineralocorticoid receptor antagonists (MRAs) have become mandated therapy in patients with reduced ejection fraction (systolic) heart failure (HF) across all symptom classes...
  30. Bossard M, Binbraik Y, Beygui F, Pitt B, Zannad F, Montalescot G, et al. Mineralocorticoid receptor antagonists in patients with acute myocardial infarction - A systematic review and meta-analysis of randomized trials. Am Heart J. 2018;195:60-69 pubmed publisher
    Although mineralocorticoid antagonists (MRAs) reduce mortality in patients with heart failure complicating myocardial infarction (MI), it is unclear if they could be beneficial to all patients with MI...
  31. Akmangit I, Aydin K, Sencer S, Topcuoglu O, Topcuoglu E, Daglioglu E, et al. Dual stenting using low-profile LEO baby stents for the endovascular management of challenging intracranial aneurysms. AJNR Am J Neuroradiol. 2015;36:323-9 pubmed publisher
    ..The 3- and 6-month control MRAs and DSAs demonstrated complete occlusion of the aneurysms in all patients except 1...
  32. Shavit L, Silberman S, Tauber R, Merin O, Bitran D, Fink D. Preoperative aldosterone receptor blockade and outcomes of cardiac surgery in patients with chronic kidney disease?. Clin Nephrol. 2017;: pubmed publisher
    ..However, continuation of MRAs before cardiac surgery in patients with CKD has never been evaluated and its potential benefit or harm in this ..
  33. Nemoto M, Hayashi N, Hanaoka S, Nomura Y, Miki S, Yoshikawa T. Feasibility Study of a Generalized Framework for Developing Computer-Aided Detection Systems-a New Paradigm. J Digit Imaging. 2017;30:629-639 pubmed publisher
    ..The CADe systems for detecting cerebral aneurysms in brain MRAs and for detecting lung nodules in chest CTs were successfully developed using the respective datasets...
  34. López Uceda A, Ayuso J, Lopez M, Jiménez J, Agrela F, Sierra M. Properties of Non-Structural Concrete Made with Mixed Recycled Aggregates and Low Cement Content. Materials (Basel). 2016;9: pubmed publisher
    ..affecting the properties analyzed in this research are the amount of cement and the replacement ratio; the two MRAs used in this work presented a similar influence on the properties...
  35. Rawnaque F, Buck J. Comparing the effect of aperture extension on the peak sidelobe level of sparse arrays. J Acoust Soc Am. 2017;142:EL467 pubmed publisher
    ..This letter compares the PSLs of minimum redundancy arrays (MRAs), minimum hole arrays (MHAs), and co-prime sensor arrays (CSAs) (conventionally beamformed and product processed) ..
  36. Wieser M, Rhyner D, Martinelli M, Suter T, Schnegg B, Bösch C, et al. [Pharmacological therapy of heart failure with reduced ejection fraction]. Ther Umsch. 2018;75:180-186 pubmed publisher
    ..symptomatic heart failure despite optimal medical therapy with ACE inhibitors or ARBs, beta-blockers, and MRAs. Crucial for all mentioned substances is to aim for the maximal tolerated dose...
  37. Butler J, Hernandez A, Anstrom K, Kalogeropoulos A, Redfield M, Konstam M, et al. Rationale and Design of the ATHENA-HF Trial: Aldosterone Targeted Neurohormonal Combined With Natriuresis Therapy in Heart Failure. JACC Heart Fail. 2016;4:726-35 pubmed publisher
    Although therapy with mineralocorticoid receptor antagonists (MRAs) is recommended for patients with chronic heart failure (HF) with reduced ejection fraction and in post-infarction HF, it has not been studied well in acute HF (AHF) ..
  38. Kempen T, Hedström M, Olsson H, Johansson A, Ottosson S, Al Sammak Y, et al. Assessment tool for hospital admissions related to medications: development and validation in older patients. Int J Clin Pharm. 2019;41:198-206 pubmed publisher
    Background Medication-related hospital admissions (MRAs) are frequently used to measure outcomes in studies involving medication reviews...
  39. Wang W, Wang J, Li N, Zhang X, Zhao W, Li J, et al. Chemopreventive flavonoids from Millettia pulchra Kurz var-laxior (Dunn) Z.Wei (Yulangsan) function as Michael reaction acceptors. Bioorg Med Chem Lett. 2015;25:1078-81 pubmed publisher
    ..The expression of NQO1 is regulated by Michael reaction acceptors (MRAs) via the Keap1/Nrf2/ARE signaling pathway...
  40. Miller R, Howlett J, Exner D, Campbell P, Grant A, Wilton S. Baseline Functional Class and Therapeutic Efficacy of Common Heart Failure Interventions: A Systematic Review and Meta-analysis. Can J Cardiol. 2015;31:792-9 pubmed publisher
    ..angiotensin-converting enzyme [ACE] inhibitors, β-blockers, mineralocorticoid receptor antagonists [MRAs], implantable cardioverter defibrillator [ICD], and cardiac resynchronization therapy [CRT]) across NYHA class...
  41. Lax A, Sánchez Más J, Asensio Lopez M, Fernandez Del Palacio M, Caballero L, Garrido I, et al. Mineralocorticoid receptor antagonists modulate galectin-3 and interleukin-33/ST2 signaling in left ventricular systolic dysfunction after acute myocardial infarction. JACC Heart Fail. 2015;3:50-8 pubmed publisher
    This study aimed to evaluate the specific role of the 2 available mineralocorticoid receptor antagonists (MRAs), eplerenone and spironolactone, on the modulation of galectin-3 (Gal-3) and interleukin (IL)-33/ST2 signaling in an ..
  42. Nakamura M, Takamiya M, Akimoto M, Ueki N, Yamada M, Tanabe H, et al. Target localization errors from fiducial markers implanted around a lung tumor for dynamic tumor tracking. Phys Med. 2015;31:934-941 pubmed publisher
    ..Pe was then calculated using three different CGs and three different MRAs. The TLE was calculated as the root-mean-square error of the difference between Pt and Pe calculated for each ..
  43. Rosselló X, Ariti C, Pocock S, Ferreira J, Girerd N, McMurray J, et al. Impact of mineralocorticoid receptor antagonists on the risk of sudden cardiac death in patients with heart failure and left-ventricular systolic dysfunction: an individual patient-level meta-analysis of three randomized-controlled trials. Clin Res Cardiol. 2019;108:477-486 pubmed publisher
    ..Mineralocorticoid receptor antagonists (MRAs) may attenuate this risk. We aimed to assess the impact of MRAs on SCD in patients with LVSD...
  44. Fukuta H, Goto T, Wakami K, Kamiya T, Ohte N. Effects of mineralocorticoid receptor antagonists on left ventricular diastolic function, exercise capacity, and quality of life in heart failure with preserved ejection fraction: a meta-analysis of randomized controlled trials. Heart Vessels. 2019;34:597-606 pubmed publisher
    ..enhancing LV diastolic dysfunction, and that aldosterone antagonists (mineralocorticoid receptor antagonists [MRAs]) prevents myocardial hypertrophy and fibrosis...
  45. Ouwerkerk W, Zwinderman A, Ng L, Demissei B, Hillege H, Zannad F, et al. Biomarker-Guided Versus Guideline-Based Treatment of Patients With Heart Failure: Results From BIOSTAT-CHF. J Am Coll Cardiol. 2018;71:386-398 pubmed publisher
    ..ACE) inhibitor/angiotensin receptor blockers (ARBs), beta-blockers, and mineralocorticoid receptor antagonists (MRAs) to doses used in randomized clinical trials, but these recommended doses are often not reached...
  46. Chen Y, Wang H, Lu Y, Huang X, Liao Y, Bin J. Effects of mineralocorticoid receptor antagonists in patients with preserved ejection fraction: a meta-analysis of randomized clinical trials. BMC Med. 2015;13:10 pubmed publisher
    Mineralocorticoid receptor antagonists (MRAs) have been shown to be effective in patients with heart failure or myocardial infarction complicated by a reduced ejection fraction...
  47. Ferreira J, Girerd N, Medeiros P, Santos M, Carvalho H, Bettencourt P, et al. Spot urine sodium excretion as prognostic marker in acutely decompensated heart failure: the spironolactone effect. Clin Res Cardiol. 2016;105:489-507 pubmed publisher
    ..Mineralocorticoid receptor antagonists (MRAs) in natriuretic doses may improve spot urine sodium excretion and outcomes...
  48. Liu T, Korantzopoulos P, Shao Q, Zhang Z, Letsas K, Li G. Mineralocorticoid receptor antagonists and atrial fibrillation: a meta-analysis. Europace. 2016;18:672-8 pubmed publisher
    ..RCTs) and observational studies in order to examine the protective role of mineralocorticoid receptor antagonists (MRAs) on AF...
  49. Ehrhardt A, Wang B, Leung M, Schrader J. Absence of M-Ras modulates social behavior in mice. BMC Neurosci. 2015;16:68 pubmed publisher
    ..In their interactions with other males, Mras(-/-) males exhibited high levels of territorial aggression and social investigations, and increased fear-related ..
  50. Shahzadi S, Shabana -, Chaudhry M, Arooj I, Hasnain S. A Single-Nucleotide Polymorphism in C12orf43 Region is Associated with the Risk of Coronary Artery Disease in a Pakistani Cohort. Biochem Genet. 2016;54:676-84 pubmed publisher
    ..We aimed to examine the association of MRAS/rs9818870 and C12orf43/rs2258287 polymorphisms with the risk of CAD in a Pakistani sample...
  51. Chen M, Dong S, Cai N, Fan M, Gu S, Zheng J, et al. Efficacy and safety of mineralocorticoid receptor antagonists for patients with heart failure and diabetes mellitus: a systematic review and meta-analysis. BMC Cardiovasc Disord. 2016;16:28 pubmed publisher
    ..The aim of this study was to systematically assess the efficacy and safety of mineralocorticoid receptor antagonists (MRAs) for patients with heart failure (HF) and diabetes mellitus (DM)...
  52. Hundemer G, Curhan G, Yozamp N, Wang M, Vaidya A. Renal Outcomes in Medically and Surgically Treated Primary Aldosteronism. Hypertension. 2018;: pubmed publisher
    Lifelong therapy with mineralocorticoid receptor antagonists (MRAs) or surgical adrenalectomy are the recommended treatments for primary aldosteronism (PA). Whether these treatments mitigate the risk for kidney disease remains unknown...
  53. Teng T, Tromp J, Tay W, Anand I, Ouwerkerk W, Chopra V, et al. Prescribing patterns of evidence-based heart failure pharmacotherapy and outcomes in the ASIAN-HF registry: a cohort study. Lancet Glob Health. 2018;6:e1008-e1018 pubmed publisher
    ..inhibitors or angiotensin II receptor blockers (ARBs), β blockers, and mineralocorticoid receptor antagonists (MRAs) are of proven benefit and are recommended by guidelines for management of patients with heart failure and reduced ..
  54. Pisoni R, Acelajado M, Cartmill F, Dudenbostel T, Dell Italia L, Cofield S, et al. Long-term effects of aldosterone blockade in resistant hypertension associated with chronic kidney disease. J Hum Hypertens. 2012;26:502-6 pubmed publisher
    ..Mineralocorticoid receptor antagonists (MRAs) are effective in the management of resistant hypertension but are not widely used in CKD because of the risk of ..
  55. Vizzardi E, Sciatti E, Bonadei I, D Aloia A, Tartière Kesri L, Tartière J, et al. Effects of spironolactone on ventricular-arterial coupling in patients with chronic systolic heart failure and mild symptoms. Clin Res Cardiol. 2015;104:1078-87 pubmed publisher
    Several studies demonstrated that mineralocorticoid receptor antagonists (MRAs) are able to prevent myocardial and vascular fibrosis, and left ventricular (LV) remodeling in patients with systolic chronic heart failure (HF) and mild ..
  56. Chen D, Lv B, Kobayashi S, Xiong Y, Sun P, Lin Y, et al. Madagascine Induces Vasodilatation via Activation of AMPK. Front Pharmacol. 2016;7:435 pubmed
    ..The effects of madagascine on vasoconstriction of rat mesenteric resistance arteries (MRAs) induced by K+, methoxamine, and endothelin-1 were, respectively, studied...
  57. Ramesh T, Kumar Panda A, Shiva Kumar S. Type-2 fuzzy logic control based MRAS speed estimator for speed sensorless direct torque and flux control of an induction motor drive. ISA Trans. 2015;57:262-75 pubmed publisher
    In this research study, a model reference adaptive system (MRAS) speed estimator for speed sensorless direct torque and flux control (DTFC) of an induction motor drive (IMD) using two adaptation mechanism schemes are proposed to replace ..
  58. Hirt M, Muttardi A, Helms T, van den Bussche H, Eschenhagen T. General practitioners' adherence to chronic heart failure guidelines regarding medication: the GP-HF study. Clin Res Cardiol. 2016;105:441-50 pubmed publisher
    ..blockers (ACEIs/ARBs), 73 % beta blocker (BBs), but only 18 % mineralocorticoid receptor antagonists (MRAs)...
  59. Irie R, Suzuki M, Yamamoto M, Takano N, Suga Y, Hori M, et al. Assessing Blood Flow in an Intracranial Stent: A Feasibility Study of MR Angiography Using a Silent Scan after Stent-Assisted Coil Embolization for Anterior Circulation Aneurysms. AJNR Am J Neuroradiol. 2015;36:967-70 pubmed publisher
    ..Nine patients treated with stent-assisted coil embolization for anterior circulation aneurysms underwent MRAs (Silent MRA and TOF MRA) and x-ray digital subtraction angiography...
  60. Gandhi P, Motiwala S, Belcher A, Gaggin H, Weiner R, Baggish A, et al. Galectin-3 and mineralocorticoid receptor antagonist use in patients with chronic heart failure due to left ventricular systolic dysfunction. Am Heart J. 2015;169:404-411.e3 pubmed publisher
    ..failure biomarker associated with aldosterone-induced myocardial fibrosis; mineralocorticoid receptor antagonists (MRAs) may reduce such fibrosis...
  61. Bazoukis G, Thomopoulos C, Tse G, Tsioufis C. Is there a blood pressure lowering effect of MRAs in heart failure? An overview and meta-analysis. Heart Fail Rev. 2018;23:547-553 pubmed publisher
    Although mineralocorticoid antagonists (MRAs) have been proposed as effective fourth-line blood pressure (BP) lowering agents in resistant hypertension, this effect in heart failure is undetermined...
  62. Bhagirath D, Zhao X, West W, Qiu F, Band H, Band V. Cell type of origin as well as genetic alterations contribute to breast cancer phenotypes. Oncotarget. 2015;6:9018-30 pubmed
    ..types designated as K5+/K19- or K5+/K19+ upon introduction of identical combinations of oncogenes-mutant H-Ras (mRas) and mutant p53 (mp53), together with either wild-type ErbB2(wtErbB2) or wild-type EGFR (wtEGFR)...
  63. Bonnard B, Pieronne Deperrois M, Djerada Z, Elmoghrabi S, Kolkhof P, Ouvrard Pascaud A, et al. Mineralocorticoid receptor antagonism improves diastolic dysfunction in chronic kidney disease in mice. J Mol Cell Cardiol. 2018;121:124-133 pubmed publisher
    ..Finerenone is a new non-steroidal MRA that shows fewer hyperkaliaemic events than the traditional steroidal MRAs and could therefore represent an alternative to these molecules in patients with damaged kidney function...
  64. Gracz A, Williamson I, Roche K, Johnston M, Wang F, Wang Y, et al. A high-throughput platform for stem cell niche co-cultures and downstream gene expression analysis. Nat Cell Biol. 2015;17:340-9 pubmed publisher
    ..We use MRAs to demonstrate that Paneth cells, a known ISC niche component, enhance organoid formation in a contact-dependent ..
  65. Chauhan V, Dev S, Pham M, Lin S, Heidenreich P. Facility variation and predictors of serum potassium monitoring after initiation of a mineralocorticoid receptor antagonist in patients with heart failure. Am Heart J. 2015;170:543-9 pubmed publisher
    Mineralocorticoid receptor antagonists (MRAs) have been shown to reduce morbidity and mortality in patients with heart failure (HF) with reduced ejection fraction but are associated with hyperkalemia...
  66. Makai P, Inthout J, Deinum J, Jenniskens K, Wilt G. A Network Meta-Analysis of Clinical Management Strategies for Treatment-Resistant Hypertension: Making Optimal Use of the Evidence. J Gen Intern Med. 2017;32:921-930 pubmed publisher
    ..Studies from recent meta-analyses for RDN and placebo effect were supplemented with a systematic search for MRAs in ATRHTN in the Pubmed, EMBASE, CINAHL and Cochrane databases through November 2016...
  67. Bonsu K, Arunmanakul P, Chaiyakunapruk N. Pharmacological treatments for heart failure with preserved ejection fraction-a systematic review and indirect comparison. Heart Fail Rev. 2018;23:147-156 pubmed publisher
    ..Evidence for mineralocorticoid antagonists (MRAs), β-adrenoceptor blockers (β-blockers), and angiotensin-converting enzyme inhibitors/angiotensin receptor ..
  68. Taghizadeh Afshari A, Mohammadi Fallah M, Alizadeh M, Makhdoomi K, Rahimi E, Vossoghian S. Outcome of Kidney Transplantation From Living Donors With Multiple Renal Arteries Versus Single Renal Artery. Iran J Kidney Dis. 2016;10:85-90 pubmed
    Receiving a kidney transplant from donors with multiple renal arteries (MRAs) is suggested to be associated with higher risk of vascular and urologic complications and poor allograft outcomes compared to the donors with single renal ..
  69. Zoli M, Manzoli L, Bonfatti R, Ruggeri A, Mariani G, Bacci A, et al. Endoscopic endonasal anatomy of the ophthalmic artery in the optic canal. Acta Neurochir (Wien). 2016;158:1343-50 pubmed publisher
    ..ophthalmic artery was analyzed through five endoscopic endonasal dissections, and 40 nonpathological consecutive MRAs were reviewed...
  70. Wang G, Hedgire S, Le T, Sonis J, Yun B, Lev M, et al. MR angiography can guide ED management of suspected acute aortic dissection. Am J Emerg Med. 2017;35:527-530 pubmed publisher
    ..Demographics, clinical assessment, CTA contraindications, outcomes, and ED disposition were analyzed. 50 MRAs were ordered for suspected thoracic aortic dissection...
  71. Dutzmann J, Bauersachs J, Sedding D. Evidence for the use of mineralocorticoid receptor antagonists in the treatment of coronary artery disease and post-angioplasty restenosis. Vascul Pharmacol. 2017;: pubmed publisher
    Mineralocorticoid receptor antagonists (MRAs), such as spironolactone and eplerenone have an established role in the treatment of heart failure...
  72. Miller R, Howlett J. Retrospective review of in hospital use of mineralocorticoid receptor antagonists for high risk patients following myocardial infarction. BMC Cardiovasc Disord. 2015;15:46 pubmed publisher
    There is little data regarding use of mineralocorticoid antagonists (MRAs) for patients reduced LV ejection fraction (LVEF) following acute myocardial infarction (MI)...
  73. Zorgani Y, Koubaa Y, Boussak M. MRAS state estimator for speed sensorless ISFOC induction motor drives with Luenberger load torque estimation. ISA Trans. 2016;61:308-317 pubmed publisher
    ..stator flux oriented controlled (ISFOC) induction motor drive based on the model reference adaptive system (MRAS) scheme. As a matter of fact, this method is meant to inter-connect a speed estimator with the load torque observer...
  74. Saqib R, Harris J, Funk L. Comparison of magnetic resonance arthrography with arthroscopy for imaging of shoulder injuries: retrospective study. Ann R Coll Surg Engl. 2017;99:271-274 pubmed publisher
    ..b>MRAs were reported by experienced musculoskeletal radiologists...
  75. Bradham W, Bell S, Adkisson D, Smith H, Harrell F, Lawson M, et al. Myocardial T1 Measurement Predicts Beneficial LV Remodeling After Long-Term Heart Failure Therapy. J Card Fail. 2017;23:262-265 pubmed publisher
    ..of CMR predicts left ventricular (LV) beneficial remodeling in NIDCM after heart failure (HF) treatment including MRAs. Twelve patients with NIDCM, on stable beta-blocker and angiotensin-converting enzyme inhibitor/angiotensin ..
  76. Kolkhof P, Bärfacker L. 30 YEARS OF THE MINERALOCORTICOID RECEPTOR: Mineralocorticoid receptor antagonists: 60 years of research and development. J Endocrinol. 2017;234:T125-T140 pubmed publisher
    ..At that time, spirolactone, the first generation of synthetic steroid-based MR antagonists (MRAs), which was identified in preclinical in vivo models, had already been in clinical use for 30 years...
  77. Kolo F, Schwitzguébel A, Kourhani A, Denard P, Charbonnier C, Lädermann A. Fosbury flop tear of the rotator cuff: diagnostic assessment with magnetic resonance arthrography. Br J Radiol. 2017;90:20170146 pubmed publisher
    ..Preoperative MRAs were consecutively performed and compared with intraoperative findings being the gold standard control...
  78. Yang J, Young M. Mineralocorticoid receptor antagonists-pharmacodynamics and pharmacokinetic differences. Curr Opin Pharmacol. 2016;27:78-85 pubmed publisher
    Mineralocorticoid receptor antagonists (MRAs) are best known as potassium-sparing diuretics due to their blockade of aldosterone action in renal epithelial tissues...
  79. Wirtwein M, Melander O, Sjögren M, Hoffmann M, Narkiewicz K, Gruchala M, et al. Relationship between selected DNA polymorphisms and coronary artery disease complications. Int J Cardiol. 2017;228:814-820 pubmed publisher
    ..The alleles of the following SNPs: rs1746048 (CXCL12), rs9818870 (MRAS) and rs17114036 (PPAP2B) were associated with a higher risk of MACE and the alleles of SNPs rs1746048 (CXCL12) and ..
  80. Khazanie P, Hammill B, Patel C, Kiernan M, Cooper L, Arnold S, et al. Use of Heart Failure Medical Therapies Among Patients With Left Ventricular Assist Devices: Insights From INTERMACS. J Card Fail. 2016;22:672-9 pubmed publisher
    ..or angiotensin receptor blockers (ARBs), 55% for β-blockers, 40% for mineralocorticoid receptor antagonists (MRAs), 87% for loop diuretics, 54% for amiodarone, 11% for phosphodiesterase inhibitors, 22% for warfarin, and 54% for ..
  81. Dev S, Hoffman T, Kavalieratos D, Heidenreich P, Wu W, Schwenke D, et al. Barriers to Adoption of Mineralocorticoid Receptor Antagonists in Patients With Heart Failure: A Mixed-Methods Study. J Am Heart Assoc. 2016;5:e002493 pubmed publisher
    Mineralocorticoid receptor antagonists (MRAs) are the most underutilized pharmacotherapy for heart failure. Minimal data are available on the barriers to MRA adoption from the perspective of prescribing clinicians...
  82. Kolkhof P, Jaisser F, Kim S, Filippatos G, Nowack C, Pitt B. Steroidal and Novel Non-steroidal Mineralocorticoid Receptor Antagonists in Heart Failure and Cardiorenal Diseases: Comparison at Bench and Bedside. Handb Exp Pharmacol. 2017;243:271-305 pubmed publisher
    ..Accordingly, the available steroidal MR antagonists (MRAs) spironolactone (first generation MRA) and eplerenone (second generation MRA) have been shown to be effective in ..
  83. Neiman M, Halshtok Neiman O, Aharoni D, Liberman B, Adar E, Eshed I. Magnetic resonance arthrography of the hip: prevalence of diagnoses not suspected by the referring physician and correlation with clinical examination and pain score. Acta Radiol. 2016;57:595-601 pubmed publisher
    ..All hip MRAs (2011-2013) were retrospectively evaluated for intra- and extra-articular pathologies in consensus by two readers...
  84. Solomon S, Claggett B, Lewis E, Desai A, Anand I, Sweitzer N, et al. Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fraction. Eur Heart J. 2016;37:455-62 pubmed publisher
    While mineralocorticoid receptor antagonists (MRAs) have been shown to benefit patients with reduced left ventricular ejection fraction (LVEF), spironolactone did not reduce the primary endpoint of cardiovascular death, heart failure ..
  85. Ehrhardt A, Wang B, Yung A, Wang Y, Kozlowski P, van Breemen C, et al. Urinary Retention, Incontinence, and Dysregulation of Muscarinic Receptors in Male Mice Lacking Mras. PLoS ONE. 2015;10:e0141493 pubmed publisher
    ..There were changes in detrusor morphology in Mras-/- males: Smooth muscle tissue, which exhibited a compact organization in WT mice, appeared disorganized and became ..
  86. Haseeb A, Winit Watjana W, Bakhsh A, Elrggal M, Hadi M, Mously A, et al. Effectiveness of a pharmacist-led educational intervention to reduce the use of high-risk abbreviations in an acute care setting in Saudi Arabia: a quasi-experimental study. BMJ Open. 2016;6:e011401 pubmed publisher
    ..preintervention) and then 498 (postintervention) handwritten physician orders, medication administration records (MRAs) and pharmacy dispensing sheets of 482 and 388 patients, respectively, from emergency wards, inpatient settings and ..
  87. Hanke M, Steppacher S, Anwander H, Werlen S, Siebenrock K, Tannast M. What MRI Findings Predict Failure 10 Years After Surgery for Femoroacetabular Impingement?. Clin Orthop Relat Res. 2017;475:1192-1207 pubmed publisher
    ..of patients with symptomatic FAI when these secondary degenerative findings were detected on preoperative radial MRAs. We retrospectively studied 121 patients (146 hips) who underwent acetabuloplasty and/or osteochondroplasty of the ..
  88. Tandon A, Byrne N, Nieves Velasco Forte M, Zhang S, Dyer A, Dillenbeck J, et al. Use of a semi-automated cardiac segmentation tool improves reproducibility and speed of segmentation of contaminated right heart magnetic resonance angiography. Int J Cardiovasc Imaging. 2016;32:1273-9 pubmed publisher
    ..Magnetic resonance angiograms (MRAs) of 19 patients undergoing intervention for right ventricular outflow lesions were segmented to demonstrate the ..
  89. Berbenetz N, Mrkobrada M. Mineralocorticoid receptor antagonists for heart failure: systematic review and meta-analysis. BMC Cardiovasc Disord. 2016;16:246 pubmed
    Mineralocorticoid receptor antagonists (MRAs) have been associated with improved patient outcomes in patients with heart failure with reduced ejection fraction (HFrEF) but not preserved ejection fraction (HFpEF)...
  90. Vukadinovic D, Lavall D, Vukadinović A, Pitt B, Wagenpfeil S, Bohm M. True rate of mineralocorticoid receptor antagonists-related hyperkalemia in placebo-controlled trials: A meta-analysis. Am Heart J. 2017;188:99-108 pubmed publisher
    ..We performed a meta-analysis including randomized, placebo-controlled trials reporting hyperkalemia on MRAs in patients after myocardial infarction or with chronic heart failure...
  91. Ansari W, Humphries S, Naveed A, Khan O, Khan D, Khattak E. Effect of Coronary Artery Disease risk SNPs on serum cytokine levels and cytokine imbalance in Premature Coronary Artery Disease. Cytokine. 2017;: pubmed publisher
    ..MIA3 rs17465637; 9p21 rs10757274; CXCL12 rs1746048; APOA5 rs662799; APOB rs1042031; LPA rs3798220; LPA 10455872; MRAS rs9818870; LPL rs328; SORT1 rs646776; PCSK9 rs11591147; APOE rs429358; APOE rs7412 in Pakistani PCAD patients and ..
  92. Sconfienza L, Albano D, Messina C, Silvestri E, Tagliafico A. How, When, Why in Magnetic Resonance Arthrography: an International Survey by the European Society of Musculoskeletal Radiology (ESSR). Eur Radiol. 2018;28:2356-2368 pubmed publisher
    ..A median of 3,000 (interquartile range: 1,567.5-5,324.5) musculoskeletal MR examinations and a median of 125.5 MRAs (50.75-249) per institution were performed in 2016. Ratio between MRA and musculoskeletal MR was 4.7% (1.6%-9.0%)...